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1. INTRODUCTION {#ccr31866-sec-0001}
===============

Diagnostic confusion can arise when acute lymphoblastic leukemia (ALL) patients present with intracytoplasmic granules which typically are found in acute myeloid leukemia (AML). Granular ALL is extremely rare in adults, and the natural history of this condition in adults is not well described. We describe a case of granular ALL in a 54‐year‐old woman and review its clinical significance in adults reported in the literature.

The presence of azurophilic granules in the cytoplasm is one of the key distinguishing features of acute myeloid leukemia (AML) which differentiates it from acute lymphoblastic leukemia (ALL). However, on rare occasions, these intracytoplasmic inclusions may be found in ALL blasts, termed granular ALL, that defy conventional teaching and diagnostic pathways.[1](#ccr31866-bib-0001){ref-type="ref"} Although uncommon, granular ALL may be found at a higher incidence in pediatric patients and may be associated with a worse prognosis in this cohort.[2](#ccr31866-bib-0002){ref-type="ref"} We review the case history and pathological findings in an adult patient with granular ALL and discuss the impact of granules on clinical outcomes in these ALL patients through a review of the literature.

2. CASE HISTORY {#ccr31866-sec-0002}
===============

A 54‐year‐old woman presented with light chain multiple myeloma three years prior and was treated with VAD (Vincristine, Adriamycin, and Dexamethasone) followed by an autologous stem cell transplant resulting in a complete response. This was followed by thalidomide maintenance therapy complicated by mild peripheral neuropathy.

The patient subsequently developed progressive neutropenia over the course of three years. Work‐up demonstrated abnormal appearing blasts and nucleated red cells on her peripheral blood white cell differential and smears. 33% of peripheral leukocytes were described as blasts. She was admitted to hospital for further work‐up and management. A bone marrow aspirate was performed. Morphologic assessment revealed approximately 15% of the marrow blasts had numerous cytoplasmic granules suggestive of an underlying acute myeloid leukemia (Figure [1](#ccr31866-fig-0001){ref-type="fig"}). However, flow cytometric immunophenotyping was positive for CD34, dim CD19, HLA‐DR, and cytoplasmic CD79a. CD13, CD33, cytoplasmic CD3, CD10, and MPO were negative. The findings were consistent with a precursor B‐cell acute lymphoblastic leukemia. There was no central nervous system (CNS) involvement as her cerebral spinal fluid (CSF) was negative.

![Bone marrow aspirate slides revealing some blasts with numerous cytoplasmic granules and some blasts with vacuoles](CCR3-7-123-g001){#ccr31866-fig-0001}

Induction chemotherapy with the standard Dana‐Farber ALL protocol was instituted with vincristine, doxorubicin, prednisone and asparaginase, as well as intrathecal methotrexate, cytarabine, and hydrocortisone. She achieved a complete remission and underwent the prophylactic CNS phase of treatment consisting of intrathecal hydrocortisone, methotrexate, and cytarabine via Ommaya reservoir, as well as CNS radiotherapy, followed by the intensification phase of the Dana‐Farber protocol for eight cycles. Following the eighth cycle of the intensification phase, she developed febrile neutropenia, decreased level of consciousness, and respiratory failure requiring intubation. She succumbed to an underlying sepsis and died approximately nine months after the initial diagnosis of her ALL.

3. DISCUSSION {#ccr31866-sec-0003}
=============

Cytoplasmic granules are one of the key morphologic features differentiating acute myeloid leukemia (AML) from acute lymphoblastic leukemia (ALL). These granules in AML are fused lysosomes and contain lysosomal enzymes and crystalline inclusions, but are rarely present in adult ALL cells.[3](#ccr31866-bib-0003){ref-type="ref"} The morphology of these granules has been characterized as membrane bound vesicles and tubular arrays.[4](#ccr31866-bib-0004){ref-type="ref"} In pediatric cases of ALL, granules present at a higher frequency. Cerezo et al[2](#ccr31866-bib-0002){ref-type="ref"} identified 56 cases of granular ALL out of 1252 pediatric ALL patients (4.5%). These cases were Sudan black and myeloperoxidase negative and positive for the French‐American‐British (FAB) morphologic criteria. Granular acute lymphoblastic leukemia is defined by more than 5% marrow blasts having at least three azurophilic cytoplasmic granules. The Pediatric Oncology Group study also found that granular ALL was more frequent amongst FAB L2 compared to FAB L1 and that those with granular lymphoblasts had a significantly lower complete remission rate and event‐free survival.

However, it is currently unknown whether granular ALL presents a different clinical outcome in adult patients. We performed an exhaustive literature search of all cases of adult granular acute lymphoblastic leukemia and found 18 cases in addition to our case (Table [1](#ccr31866-tbl-0001){ref-type="table"}). The mean age of the 20 adult patients was 43 years (range 20‐63) with 7 men and 12 women. The mean hemoglobin, white blood cell count, and platelet count at time of diagnosis were 7.8 g/dL, 37.3 × 10^9 ^cells/L, and 99.1 × 10^9 ^cells/L, respectively. The mean percentage of blast cells with granules was 39% (range 15‐98). All patients were MPO negative where data were available. Most patients were also CD10 positive, with two exceptions, one of which is our case. All patients where data were available were FAB group L2, which is consistent with the pediatric finding of increased granular ALL rates in that group. Most cases of granular ALL were of B‐cell lineage origin and most cases were primary leukemias. A variety of chemotherapeutic regimens were applied. The complete remission rate to induction chemotherapy was 53% which is lower than the rates reported in the literature for non‐granular adult ALL (80%‐90%).[5](#ccr31866-bib-0005){ref-type="ref"} The mean overall survival at the date of publication was 8.25 months compared to a five‐year overall survival of 30% for non‐granular patients.[6](#ccr31866-bib-0006){ref-type="ref"}

###### 

Characteristics and outcomes of 20 adult granular acute lymphoblastic leukemia cases

  Author                                                    Year reported   Age   Sex   Hgb g/dL   WBC 10^9^ cells/L   Plt 10^9^ cells/L   \% peripheral blasts granular   FAB   MPO   CD10   CD19   CD33   T‐cell antigens   B cell vs T cell   Primary vs. secondary   Treatment                                              Complete response   Survival (mo)   Cause of death
  --------------------------------------------------------- --------------- ----- ----- ---------- ------------------- ------------------- ------------------------------- ----- ----- ------ ------ ------ ----------------- ------------------ ----------------------- ------------------------------------------------------ ------------------- --------------- -----------------------
  Present case                                              2017            54    F     11.1       1.6                 173                 15                                    Neg   Neg    Pos    Neg                                         Secondary               Dana‐Farber protocol                                   Y                   9               Sepsis
  Xu[7](#ccr31866-bib-0007){ref-type="ref"}                 2017            63    F                                                                                              Neg   Pos    Pos           Neg               B                  Primary                                                                                                            
  Kishore[8](#ccr31866-bib-0008){ref-type="ref"}            2016            40    F     9.7        60                  180                 32                                    Neg   Pos    Pos           Neg               B                  Primary                                                                        Y                                   
  Agarwal[9](#ccr31866-bib-0009){ref-type="ref"}            2010            50    M     3.6        17.8                23                  22                                    Neg   Pos    Pos    Pos    Neg               B                  Primary                 MCP‐841                                                N                                   Died during induction
  Anand[10](#ccr31866-bib-0010){ref-type="ref"}             2008            30    F     5.4        20                  20                  22                              L2    Neg   Pos    Pos    Neg    Neg               B                  Primary                                                                                                            
  Pitman[11](#ccr31866-bib-0011){ref-type="ref"}            2007            45    F                1.2                                     25                              L2    Neg   Neg                  Neg               B                  Secondary               VAD, thalidomide and dexamethasone, hyper‐CVAD         Y                                   
  Fulcher[3](#ccr31866-bib-0003){ref-type="ref"}            2006            56    F     4.1        2.9                 26                  10                                    Neg   Pos    Pos           Neg               B                  Primary                 Hyper‐CVAD                                             Y                   7               
  Morita[12](#ccr31866-bib-0012){ref-type="ref"}            2002            58    F     5.3        33.5                72                  84                              L2          Pos    Pos    Pos                      B                  Primary                                                                        Y                   6               
  Bolado‐Martinez[13](#ccr31866-bib-0013){ref-type="ref"}   1997            52    M                167                                     98                              L2          Pos    Pos    Neg                      B                  Primary                 TOTAL XI                                               N                   0.5             Hemopytysis
  Bolado‐Martinez[13](#ccr31866-bib-0013){ref-type="ref"}   1997            20    F                36                                      86                              L2          Pos    Pos    Neg                      B                  Primary                                                                        N                   0.75            Severe septicemia
  Schwarzinger[14](#ccr31866-bib-0014){ref-type="ref"}      1993            38    M     8.6        18.7                113                 45                              L2    Neg   Pos    Pos    Neg    Neg               B                  Primary                 BMFT protocol                                          Y                   8               
  Tauchi[15](#ccr31866-bib-0015){ref-type="ref"}            1991            58    F                26.6                                    30                              L2    Neg   Pos    Pos    Neg                      B                  Primary                 Combination chemotherapy                               Y                                   
  Canta‐Rajnoldi[4](#ccr31866-bib-0004){ref-type="ref"}     1989            22    M     8.5        31.2                99                  25                              L2    Neg   Pos    Neg    Neg                      B                  Primary                 Vincristine, daunorubicin, Ara‐C, prednisone           Y                   27              
  Canta‐Rajnoldi[4](#ccr31866-bib-0004){ref-type="ref"}     1989            58    M     8.2        1.7                 2.3                 47                              L2    Neg   Pos    Pos    Neg                      B                  Primary                 Vincristine, daunorubicin, Ara‐C, prednisone           N                   8               
  Canta‐Rajnoldi[4](#ccr31866-bib-0004){ref-type="ref"}     1989            38    M     6.3        2.2                 44                  41                              L2    Neg   Pos    Pos    Neg                      B                  Primary                 Vincristine, daunorubicin, Ara‐C, prednisone           N                   14              
  Canta‐Rajnoldi[4](#ccr31866-bib-0004){ref-type="ref"}     1989            21    F     9.8        80.0                243                 30                              L2    Neg   Pos    Neg    Neg                      B                  Primary                 Vincristine, daunorubicin, Ara‐C, prednisone           N                   7               
  Hay[1](#ccr31866-bib-0001){ref-type="ref"}                1987            20    M     6.5        12.6                68                  30                              L2    Neg   Pos    Neg           Neg               B                  Primary                 Vincristine, daunorubicin, asparginase, prednisolone   N                   7               
  Hay[1](#ccr31866-bib-0001){ref-type="ref"}                1987            54    F     7.1        0.4                 60                  25                              L2    Neg   Pos    Pos           Neg               B                  Primary                 Vincristine, daunorubicin, asparginase, prednisolone   N                   1               Aspergillus pneumonia
  Fradera[16](#ccr31866-bib-0016){ref-type="ref"}           1986            45    F     14.7       158                 264                 35                                                               Pos               T                  Primary                 Vincristine, Prednisone                                Y                   12              Sepsis

Hgb, hemoglobin; WBC, white blood cell; Plt, platelet; FAB, French‐American‐British Classification; MPO, myeloperoxidase; VAD, vincristine, doxorubicin, dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone.
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The heterogeneity in presentation of these cases imparts difficulty in the analysis and categorization of adult granular acute lymphoblastic leukemia. Limitations of our review of the literature include missing data in the described cases as well as the diversity in patient, disease characteristics, and treatment modalities described. The rarity of granular ALL also limits statistical analysis, further generalization, and adequate assessment of subgroups of ALL.

4. CONCLUSION {#ccr31866-sec-0004}
=============

An accurate diagnosis is critically important for treatment implementation and prognosis in acute leukemia. Diagnostic confusion may arise in acute lymphoblastic leukemia with cytoplasmic granular inclusions resembling that of acute myeloid leukemia. It is important to confirm the type of acute leukemia with flow cytometric immunophenotyping in all cases. In this review of the literature, granular ALL in adults results in a worse prognosis compared to non‐granular adult ALL patients which is consistent with the finding in pediatric granular ALL patients.
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